Immunoassay Market Thriving: Predicted US$53 Billion Valuation by 2032

The global Immunoassay Market is expected to increase steadily, with a projected annual growth rate of 6% between 2022 and 2032. By the end of this period, it is estimated to reach a market value of US$ 53 billion. In 2021, the market was valued at US$ 28 billion, and it is anticipated to grow to US$ 29.6 billion in 2022, marking a year-on-year growth rate of 5.7%.

𝗚𝗲𝘁 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝗽𝘆:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4766

The market's growth can be attributed to the rising prevalence of chronic and infectious diseases, including COVID-19. Furthermore, the increasing elderly population, which is more susceptible to such health conditions, is expected to contribute to the market's expansion.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗗𝗿𝗶𝘃𝗲𝘀:

Increasing Disease Burden:

With the rising prevalence of chronic diseases like cancer, cardiovascular diseases, and infectious diseases, there's a growing need for accurate and timely diagnosis. Immunoassays offer a reliable method for detecting biomarkers associated with these conditions, aiding in early detection and effective management.

Advancements in Technology:

Technological advancements have led to the development of highly sensitive immunoassay platforms, such as enzyme-linked immunosorbent assays (ELISA), chemiluminescent immunoassays (CLIA), and fluorescence immunoassays (FIA). These platforms enable rapid detection of target molecules with improved accuracy, driving their adoption in clinical laboratories and research settings.

Expanding Applications:

Immunoassays are not only used in clinical diagnostics but also find applications in pharmaceutical and biotechnology industries for drug discovery, monitoring therapeutic efficacy, and assessing immune responses. The versatility of immunoassay platforms contributes to their widespread adoption across various sectors, fueling market growth.

Increasing Healthcare Expenditure:

Governments and private healthcare organizations are investing significantly in healthcare infrastructure and diagnostic services to address the growing healthcare needs of populations worldwide. This increased investment translates into a higher demand for diagnostic technologies like immunoassays, supporting market expansion.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗢𝘂𝘁𝗹𝗼𝗼𝗸:

Integration of Automation:

The future of immunoassay platforms lies in automation, with the integration of robotics and artificial intelligence (AI) to streamline workflow processes and enhance efficiency. Automated immunoassay systems will enable high-throughput analysis, reduce turnaround times, and minimize errors, thereby improving diagnostic accuracy and laboratory productivity.

Point-of-Care Testing (POCT):

There's a growing trend towards the development of immunoassay-based point-of-care testing devices that offer rapid and on-site diagnosis without the need for centralized laboratory facilities. POCT immunoassay devices empower healthcare professionals to make real-time clinical decisions, especially in resource-limited settings or during emergencies, driving their adoption in diverse healthcare settings.

Emergence of Multiplex Assays:

Multiplex immunoassays capable of detecting multiple analytes simultaneously are gaining traction due to their ability to provide comprehensive diagnostic information from a single sample. The future development of multiplex immunoassay platforms will focus on enhancing multiplexing capabilities, improving assay sensitivity, and reducing assay complexity, making them indispensable tools in personalized medicine and disease profiling.

Focus on Personalized Medicine:

Immunoassays will play a crucial role in the era of personalized medicine, where treatments are tailored to individual patient characteristics. By identifying specific biomarkers associated with disease susceptibility, progression, and response to therapy, immunoassays will enable healthcare providers to deliver personalized and targeted interventions, leading to improved patient outcomes and healthcare efficiency.

𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗙𝗼𝗿 𝗙𝗥𝗘𝗘 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗥𝗲𝗽𝗼𝗿𝘁:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4766

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀:

DiaSorin S.p.A.
Sysmex Corporation
bioMerieux SA
Ortho Clinical Diagnostics
Thermo Fisher Scientific Inc.
Becton
Dickinson and Company
Merck KGaA.

𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

BioFire Diagnostics, a company specializing in molecular biology and a subsidiary of BioMérieux SA, submitted an application to the Food and Drug Administration (FDA) in January 2020. They sought clearance for their BIOFIRE Blood Culture Identification 2 (BCID2) Panel. This new panel offers an expanded list of antibiotic resistance genes, detects more pathogens, and includes several updated targets compared to the previous version, the BIOFIRE BCID Panel.

In November 2020, Siemens Healthineers announced that their SARS-CoV-2 IgG Antibody Test had received certification as a CE mark measurement of neutralizing antibodies. This test is an upgraded version of their earlier COVID-19 antibody test.

Snibe Diagnostics introduced the Maglumi HIV Ab/Ag Combi CLIA kit, a fourth-generation chemiluminescence immunoassay, in April 2021. This kit can identify both HIV-1 and HIV-2 antibodies, as well as the HIV-1 p24 antigen. It obtained CE marking, allowing its sale in the European Union and other regions that recognize this designation.

𝗕𝗿𝗼𝘄𝘀𝗲 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 @ https://www.factmr.com/report/4766/immunoassay-market

𝗠𝗮𝗿𝗸𝗲𝘁 𝗞𝗲𝘆 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻:

By Technology Type :
Chemiluminescence Immunoassay (CLIA)
Enzyme Linked Fluorescence Assay (ELFA)
Enzyme-linked Immunosorbent Assay (ELISA)
Radioimmunoassay (RIA)
Others

By Product :
Analyzer Immunoassay
Consumable Immunoassay

By Application :
Infectious Diseases
Orthopedics
Cardiology
Oncology
Endocrinology
Other Applications

By End-User :
Immunoassay for Blood Banks
Immunoassay for Hospitals & Diagnostic Laboratories
Immunoassay for Others (Pharmaceutical & Biotech Companies, Forensic Labs, Academic & Research Institutes, etc.)

By Region :
North America
Western Europe
Asia Pacific
Middle East & Africa
Eastern Europe
Latin America

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

𝐀𝐛𝐨𝐮𝐭 𝐅𝐚𝐜𝐭.𝐌𝐑
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.